Ositinib is mainly indicated for first- or second-line targeted therapy for lung adenocarcinoma, for patients with genetic testing, with EGFR-sensitive mutations or EGFR T790M mutations. If oxitinib becomes resistant, subsequent treatment with chemotherapy or radiation therapy may be considered and may be effective. There are other immunotherapies, such as pd-1 monoclonal antibody for lung cancer, which can also be considered. There is also a targeted drug called Anrotinib, which can be used as third-line targeted therapy for lung cancer after Ocetinib resistance, but the specific effect can only be seen while treatment. If all targeted therapies are not available, chemotherapy can be considered to control the progression of the disease.